Research graph
References from BRCA1/2 Carriers With Breast‐Ovarian Double Primary Cancers Versus Ovarian Cancer Alone: Mutation Profiles and Survival Outcomes. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer Statistics, 2025
2025 · External reference
Ovarian Cancer: A Review
10.1001/jama.2025.9495 · 2025 · External reference
Global Epidemiology of Epithelial Ovarian Cancer
10.1038/s41571-024-00881-3 · 2024 · External reference
Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers
10.1158/2159-8290.cd-24-1326 · 2025 · External reference
Risk of Second Non‐Breast Primary Cancer in Chinese Breast Cancer Patients With Germline BRCA1/2 Pathogenic Variants
10.1007/s10549-025-07886-1 · 2026 · External reference
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
10.1001/jama.2017.7112 · 2017 · External reference
Germline Mutations of the BRCA1 Gene in Breast and Ovarian Cancer Families Provide Evidence for a Genotype‐Phenotype Correlation
10.1038/ng1295-428 · 1995 · External reference
Variation of Risks of Breast and Ovarian Cancer Associated With Different Germline Mutations of the BRCA2 Gene
10.1038/ng0197-103 · 1997 · External reference
Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
10.1001/jama.2014.5985 · 2015 · External reference
Outcome of Ovarian Cancer After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
10.1038/bjc.2016.333 · 2016 · External reference
Clinical Characteristics and Survival Outcomes of Patients With Both Primary Breast Cancer and Primary Ovarian Cancer
10.1097/md.0000000000021560 · 2020 · External reference
PARPis Response and Outcome of Ovarian Cancer Patients With BRCA1/2 Germline Mutation and a History of Breast Cancer
10.3802/jgo.2024.35.e51 · 2024 · External reference
Breast Cancer Incidence and Subtype Patterns Among BRCA‐Mutated Ovarian Cancer Patients: A Systematic Review and Meta‐Analysis
10.1038/s41416-025-03320-x · 2026 · External reference
BRCA Functional Domains Associated With High Risk of Multiple Primary Tumors and Domain‐Related Sensitivity to Olaparib: The Prometheus Study
10.1016/j.esmoop.2024.104076 · 2025 · External reference
Development and Validation of an Ovarian Cancer Risk Assessment Tool for First‐Degree Relatives of Patients in the Chinese Population
10.1016/j.ygyno.2025.03.017 · 2025 · External reference
A Novel BRCA Mutation Classification System Reveals Differential Responses to PARP Inhibition and Prognostic Outcomes in Epithelial Ovarian Cancer: A Multicenter Study
10.1016/j.esmoop.2026.106060 · 2026 · External reference
BRCA2 Function in DNA Binding and Recombination From a BRCA2‐DSS1‐ssDNA Structure
10.1126/science.297.5588.1837 · 2002 · External reference
Replication Gap Suppression Depends on the Double‐Strand DNA Binding Activity of BRCA2
10.1038/s41467-023-36149-0 · 2023 · External reference
The Risk of Primary and Contralateral Breast Cancer After Ovarian Cancer in BRCA1/BRCA2 Mutation Carriers: Implications for Counseling
10.1002/cncr.27839 · 2013 · External reference
Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers
10.1001/jamasurg.2014.1081 · 2014 · External reference
Breast Cancer Incidence in BRCA Mutation Carriers With Ovarian Cancer: A Longitudal Observational Study
10.1016/j.ygyno.2021.06.009 · 2021 · External reference
Ovarian Cancer After Breast Cancer in Women With a BRCA1 or BRCA2 Pathogenic Variant
10.1016/j.ygyno.2025.07.030 · 2025 · External reference
The Role of Risk‐Reducing Surgery in Hereditary Breast and Ovarian Cancer
10.1056/nejmra1503523 · 2016 · External reference
Long‐Term Health Outcomes of Bilateral Salpingo‐Oophorectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers With Personal History of Breast Cancer: A Retrospective Cohort Study Using Linked Electronic Health Records
10.1016/s1470-2045(25)00156-1 · 2025 · External reference
Breast Cancer After Ovarian Cancer in BRCA1 and BRCA2 Pathogenic Variant Heterozygotes: Lower Rates for 5 Years Post Chemotherapy
10.1016/j.gim.2024.101172 · 2024 · External reference
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2
10.1200/jco-25-01648 · 2026 · External reference
Olaparib Plus Bevacizumab as First‐Line Maintenance in Ovarian Cancer
10.1056/nejmoa1911361 · 2019 · External reference
Poly(ADP‐Ribose) Polymerase Inhibition: Past, Present and Future
10.1038/s41573-020-0076-6 · 2020 · External reference
Olaparib Plus Bevacizumab First‐Line Maintenance in Ovarian Cancer: Final Overall Survival Results From the PAOLA‐1/ENGOT‐ov25 Trial
10.1016/j.annonc.2023.05.005 · 2023 · External reference
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers
10.1177/0003134820964208 · 2020 · External reference
Breast Cancer Outcomes in Women With Ovarian Cancer and a Pathogenic Germline BRCA Mutation
10.1016/j.ejso.2024.109380 · 2025 · External reference
Breast Cancer Surveillance for Epithelial Ovarian Cancer Patients With BRCA1 and BRCA2 Pathogenic Variants: A Single‐Center Retrospective Study
10.1093/jjco/hyaf010 · 2025 · External reference
Prophylactic Window Therapy With the Clinical Poly(ADP‐Ribose) Polymerase Inhibitor Olaparib Delays BRCA1‐Deficient Mammary Tumour Formation in Mice
10.1002/path.4857 · 2017 · External reference
The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1‐Deficient Mice
10.1158/1940-6207.capr-14-0047 · 2014 · External reference
Association of Location of BRCA1 and BRCA2 Mutations With Benefit From Olaparib and Bevacizumab Maintenance in High‐Grade Ovarian Cancer: Phase III PAOLA‐1/ENGOT‐ov25 Trial Subgroup Exploratory Analysis
10.1016/j.annonc.2022.11.003 · 2023 · External reference
Benefit From Maintenance With PARP Inhibitor in Newly Diagnosed Ovarian Cancer According to BRCA1/2 Mutation Type and Site: A Multicenter Real‐World Study
10.1016/j.esmoop.2025.104533 · 2025 · External reference
